Nathalie Assayag-Asherie

Learn More
CD44 is a multistructural and multifunctional glycoprotein, the diversity of which is generated by alternative splicing. In this communication we review some aspects related to CD44 structure and function in experimental autoimmune inflammation, focusing on research performed in our own laboratory. We have found that CD44 targeting by antibody, passively(More)
Citation: Schipp C, Nabhani S, Bienemann K, Simanovsky N, Kfir-Erenfeld S, Assayag-Asherie N, Oommen PT, Revel-Vilk S, Hönscheid A, Gombert M, Ginzel S, Schäfer D, Laws H-J, Yefenof E, Fleckenstein B, Borkhardt A, Stepensky P, and Fischer U. Specific antibody deficiency and autoinflammatory disease extend the clinical and immunological spectrum of(More)
Glucocorticoid (GC) hormones are an important ingredient of leukemia therapy since they are potent inducers of lymphoid cell apoptosis. However, the development of GC resistance remains an obstacle in GC-based treatment. In the present investigation we found that miR-103 is upregulated in GC-sensitive leukemia cells treated by the hormone. Transfection of(More)
CD44 is a multi-functional receptor with multiple of isoforms engaged in modulation of cell trafficking and transmission of apoptotic signals. We have previously shown that injection of anti-CD44 antibody into NOD mice induced resistance to type 1 diabetes (T1D). In this communication we describe our efforts to understand the mechanism underlying this(More)
Human Antibodies & Hybridomas November 7–9, 2012, Orlando, FL, USA Hyaluronic Acid Target Receptors (CD44 and RHAMM) involved in treatment of type 1 diabetes Nathalie Assayag-Asherie, Itamar Raz, Eva A. Turley and David Naor The Hebrew UniversityFaculty of Medicine, Israel Hadassah University Hospital, Israel D-Cure, Israel London Region Cancer Center,(More)
  • 1